Sunshine Biopharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Sunshine Biopharma Inc., a Colorado corporation and emerging growth company, on December 22, 2021, covering events occurring on December 20, 2021. The company is headquartered in Pointe-Claire, Quebec, Canada.
Key Financial Metrics
This filing does not report comprehensive financial statements, revenue, profit, or cash flow metrics. The primary financial event reported is the conversion of debt into equity:
- Debt Converted: $1,361,000 in convertible debt.
- Shares Issued: 2,904,833 shares of Common Stock.
- Conversion Price: Average of $0.47 per share.
- Counterparty: RB Capital Partners, Inc.
Material Changes
The material change reported is the reduction of the company's debt load by $1,361,000 and a corresponding increase in outstanding common stock by 2,904,833 shares. The transaction was executed under the exemption from registration provided by Section 4(2) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) regarding the transaction but does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies within the text of this report. The filing notes the company's status as an emerging growth company.
Investor Verification Checklist
- Verify the total outstanding share count post-conversion to assess dilution impact.
- Review the attached press release (Exhibit 99.1) for additional context on the relationship with RB Capital Partners.
- Confirm the remaining balance of convertible debt obligations not included in this specific conversion.
- Check subsequent filings for any updated liquidity positions following this debt reduction.